Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 5
1980 31
1981 10
1982 14
1983 15
1984 15
1985 16
1986 14
1987 22
1988 20
1989 30
1990 17
1991 30
1992 21
1993 31
1994 24
1995 26
1996 32
1997 28
1998 46
1999 51
2000 46
2001 84
2002 97
2003 121
2004 135
2005 143
2006 182
2007 188
2008 193
2009 206
2010 223
2011 239
2012 236
2013 213
2014 222
2015 234
2016 230
2017 207
2018 246
2019 183
2020 200
2021 204
2022 206
2023 182
2024 66

Text availability

Article attribute

Article type

Publication date

Search Results

4,480 results

Results by year

Filters applied: . Clear all
Page 1
Impact of fenofibrate on NAFLD/NASH: A genetic perspective.
Mahmoudi A, Jamialahmadi T, Johnston TP, Sahebkar A. Mahmoudi A, et al. Drug Discov Today. 2022 Aug;27(8):2363-2372. doi: 10.1016/j.drudis.2022.05.007. Epub 2022 May 17. Drug Discov Today. 2022. PMID: 35569762 Review.
In the present review, we discuss the direct or indirect impact of fenofibrate on genes involved at various stages in the progression of NAFLD. Moreover, we have reviewed studies that compare fenofibrate with other drugs in treating NAFLD, as well as recent clinical …
In the present review, we discuss the direct or indirect impact of fenofibrate on genes involved at various stages in the progression …
Role of fenofibrate in multiple sclerosis.
Abulaban AA, Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E, Alanazi A, Alexiou A, Papadakis M, Batiha GE. Abulaban AA, et al. Eur J Med Res. 2024 Feb 9;29(1):113. doi: 10.1186/s40001-024-01700-2. Eur J Med Res. 2024. PMID: 38336772 Free PMC article. Review.
Fenofibrate inhibits differentiation of Th17 by inhibiting the expression of pro-inflammatory signaling. According to these findings, this review intended to illuminate the mechanistic immunoinflammatory role of fenofibrate in mitigating MS neuropathology. In conclu
Fenofibrate inhibits differentiation of Th17 by inhibiting the expression of pro-inflammatory signaling. According to these findings,
Fenofibrate: a review of its use in dyslipidaemia.
McKeage K, Keating GM. McKeage K, et al. Drugs. 2011 Oct 1;71(14):1917-46. doi: 10.2165/11208090-000000000-00000. Drugs. 2011. PMID: 21942979 Review.
The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-alpha. ...Fenofibrate is generally well tolerated when administered alone or in combination with a statin. ...
The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-alpha. ... …
Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice.
Lee J, Jeon S, Lee M, Yoon M. Lee J, et al. Nutr Diabetes. 2023 Nov 7;13(1):19. doi: 10.1038/s41387-023-00249-z. Nutr Diabetes. 2023. PMID: 37935669 Free PMC article.
Fenofibrate improved mild hyperglycemia, severe hyperinsulinemia, and glucose tolerance in these mice. ...Treatment with fenofibrate reduced tumor necrosis factor alpha (TNFalpha) mRNA levels in adipose tissue and lowered serum TNFalpha levels. ...
Fenofibrate improved mild hyperglycemia, severe hyperinsulinemia, and glucose tolerance in these mice. ...Treatment with fenofibra
Fenofibrate for Treating Diabetic Eye Disease.
Simó R, Hernández C. Simó R, et al. Diabetes. 2023 Jul 1;72(7):838-840. doi: 10.2337/dbi22-0037. Diabetes. 2023. PMID: 37339356 No abstract available.
Fenofibrate and diabetic retinopathy.
Fagan XJ, Chong EW. Fagan XJ, et al. Clin Exp Ophthalmol. 2015 May-Jun;43(4):297-9. doi: 10.1111/ceo.12539. Clin Exp Ophthalmol. 2015. PMID: 26099043 No abstract available.
Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
Simó R, Roy S, Behar-Cohen F, Keech A, Mitchell P, Wong TY. Simó R, et al. Curr Med Chem. 2013;20(26):3258-66. doi: 10.2174/0929867311320260009. Curr Med Chem. 2013. PMID: 23745548 Review.
There is now consistent evidence from two major trials, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study and the Action to Control Cardiovascular Risk in Diabetes Eye (ACCORD-Eye) study, totalling 11,388 people with type 2 diabetes (5,701 treated w …
There is now consistent evidence from two major trials, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study and …
Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice.
Zhang D, Ma Y, Liu J, Wang D, Geng Z, Wen D, Chen H, Wang H, Li L, Zhu X, Wang X, Huang M, Zou C, Chen Y, Ma L. Zhang D, et al. Eur J Pharmacol. 2023 Dec 5;960:176159. doi: 10.1016/j.ejphar.2023.176159. Epub 2023 Oct 28. Eur J Pharmacol. 2023. PMID: 37898287 Free article.
Here, we found that fenofibrate dramatically modulate the gut microbiota composition of high-fat diet (HFD)-induced NAFLD mouse model, and the change of gut microbiota composition is dependent on TFEB-autophagy axis. Furthermore, we also found that fenofibrate impro …
Here, we found that fenofibrate dramatically modulate the gut microbiota composition of high-fat diet (HFD)-induced NAFLD mouse model …
Use of fenofibrate for intrahepatic cholestasis of pregnancy.
Grady J, Clifford C, Treadwell MC, Parikh ND, Satishchandran A. Grady J, et al. J Hepatol. 2023 Aug;79(2):e84-e86. doi: 10.1016/j.jhep.2023.04.014. Epub 2023 Apr 20. J Hepatol. 2023. PMID: 37084798 No abstract available.
Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson RS. Rosenson RS. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1319-30. doi: 10.1586/14779072.6.10.1319. Expert Rev Cardiovasc Ther. 2008. PMID: 19018684 Review.
Treatment with fenofibrate lowers triglycerides, raises HDL-cholesterol and decreases concentrations of small LDL-cholesterol particles and apolipoprotein B. Fenofibrate is particularly effective for reducing postprandial VLDL and LDL particle concentrations, and th …
Treatment with fenofibrate lowers triglycerides, raises HDL-cholesterol and decreases concentrations of small LDL-cholesterol particl …
4,480 results